A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors
NCT ID: NCT05302843
Last Updated: 2022-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
40 participants
INTERVENTIONAL
2021-03-22
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of BPI-460372 in Advanced Solid Tumor Patients
NCT05789602
A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
NCT05315180
A Study of BPI-452080 in Subjects With Solid Tumors
NCT05843305
BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors
NCT05869240
A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors
NCT05329298
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dose exploration and dose expansion
Patients receive BPI-28592 PO. Cycles repeat every 28 days.
BPI-28592
Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BPI-28592
Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age
* Measurable or evaluable disease
* Adequate organ function as defined per protocol
Exclusion Criteria
* Pregnancy or lactation
* Other protocol specified criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Betta Pharmaceuticals Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hongming Pan, Ph.D
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Sheng J, Chen H, Fu B, Pan H, Wang J, Han W. BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors. NPJ Precis Oncol. 2024 Sep 11;8(1):198. doi: 10.1038/s41698-024-00686-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BTP-661211
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.